Natalie McNamee

Natalie McNamee

Private Equity Investor at Tarnagulla Ventures Pty Ltd.

Consumer Services
Health Technology
Finance

Profile

Natalie has been a Director of Tarnagulla Ventures Pty Ltd since 2015.
She had led the investment diligence into most of the portfolio companies since then, including Lubris BioPharma, a company which has since successfully licensed their lead indication to Novartis.
Prior to returning to Australia, Natalie worked for Tocagen Inc, a gene therapy company, based in San Diego, in their business development team whilst finishing her Masters.
She then worked as a bioengineer at the then-newly formed Quanticel Pharmaceuticals, a cancer stem cell focused drug developer.
Quanticel was acquired by Celgene for $485M in 2015.
Natalie received her Masters in Bioengineering at UC San Diego and a dual Bachelor of Finance and Mechanical Engineering from Melbourne University.

Natalie McNamee active positions

CompaniesPositionStart
Private Equity Investor 2014-12-31
All active positions of Natalie McNamee

Former positions of Natalie McNamee

Training of Natalie McNamee

University of California San Diego Graduate Degree
University of Melbourne Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Natalie McNamee's experience

Connections

1

1st degree connections

4

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies2

Health Technology

Finance

See company connections
  1. Stock Market
  2. Insiders
  3. Natalie McNamee